Peptide Therapy Foundations: Metabolic Balance
Course Details
This course examines the peptides reshaping metabolic medicine: the incretin mimetics and related agents that act on appetite, glucose handling, and body weight. It is written for clinicians who want a working understanding of how each agent engages its receptors, what the trial evidence shows, and how the options differ as the class expands from single-pathway drugs toward multi-receptor designs.
The lessons move along a spectrum of mechanism. Liraglutide and Semaglutide act as GLP-1 receptor agonists. Tirzepatide adds GIP activity for dual agonism, and Retatrutide extends that further into triple GIP, GLP-1, and glucagon receptor activity. Cagrilintide works through the amylin pathway, and Setmelanotide targets the melanocortin 4 receptor for specific genetic forms of obesity. Together they show how receptor selectivity and combination shape the metabolic effect.
Each lesson follows the same clinical lens: what the agent is, how it works, what the evidence shows, and what a practitioner weighs before applying it. The result is a comparative map of the metabolic class that lets you reason about any single agent in the context of its alternatives.
SSRP FACULTY
William Seeds, MD
William Seeds, MD
William Seeds, MD
Before establishing the SSRP Institute, Dr. Seeds served as a board-certified orthopedic surgeon and sports medicine specialist for nearly three decades, including Chief of Surgery, Orthopedic Residency Site Director, and Director of The Ohio Bone & Joint Institute for University Hospitals.
His significant contributions to sports medicine have been recognized at the NFL Hall of Fame. He has consulted for athletes across all major sports leagues, including the NFL, NHL, MLB, NBA, and even the performers on “Dancing with the Stars.”
Through his research at the SSRP Institute, Dr. Seeds continues to explore the cellular pathways and mechanisms that positively impact disease and dysfunction in the body as well as optimize physical performance.
Liraglutide
In-ProgressLesson Resources
Overview
Liraglutide is a GLP-1 receptor agonist and incretin mimetic, an acetylated 31 amino acid peptide marketed as Victoza for type 2 diabetes and Saxenda for obesity. It shares 97 percent homology with native GLP-1. A fatty acid modification at lysine 26 enables reversible albumin binding, which slows clearance, blocks degradation by dipeptidyl peptidase 4, and extends the half life to roughly 13 hours. This supports once daily subcutaneous dosing, in contrast to the one to two minute half life of native GLP-1.
The FDA approved liraglutide for type 2 diabetes in 2010, for obesity in 2014, for cardiovascular risk reduction in 2017, and for pediatric obesity in patients over age 12 in 2020.
How it works
Receptor activation drives a cyclic AMP and PKA cascade that promotes glucose-dependent insulin secretion, a design that limits hypoglycemic risk when glucose is absent. EPAC2 and RAP1 signaling, tied to intracellular calcium, mediate exocytosis of insulin granules. Liraglutide also suppresses glucagon in a glucose-dependent manner without impairing the counterregulatory response to hypoglycemia, delays gastric emptying to blunt postprandial glucose excursions, and crosses the blood brain barrier to act on hypothalamic appetite centers. Additional pathways discussed include AMPK activation, NF-kB suppression, SIRT1 upregulation, and NRF2-driven antioxidant defense, several of which rest on preclinical data.
Trial evidence
The LEADER trial in roughly 9,000 high-risk type 2 diabetes patients showed about a 13 percent reduction in major adverse cardiovascular events, a 22 percent reduction in cardiovascular death, and a 15 percent reduction in all-cause mortality over 3.8 years, alongside renal benefit. The SCALE program reported mean weight loss near 8 percent versus 2.6 percent for placebo, with the 3 milligram dose statistically superior to 1.8 milligrams for weight outcomes. Liraglutide was the first GLP-1 receptor agonist to demonstrate cardiovascular mortality reduction in type 2 diabetes.
Clinical application
Dr. Seeds emphasizes slow titration, often six to twelve weeks rather than rapid escalation, to limit nausea and GI symptoms. A weight loss target near 0.5 to 0.75 pounds per week, paired with adequate protein, nutrition, and exercise, aims to preserve lean mass and reduce aesthetic concerns. Baseline labs, an eye exam, and longitudinal monitoring of weight, body composition, A1C, heart rate, and mental status support a measured approach.
Key clinical points
- Albumin binding via a lysine 26 fatty acid modification extends the half life to about 13 hours, enabling once daily subcutaneous dosing.
- LEADER showed roughly a 13 percent MACE reduction; SCALE showed mean weight loss near 8 percent versus placebo.
- Glucose-dependent insulin secretion limits hypoglycemia risk, and glucagon suppression spares the counterregulatory response.
- Slow titration helps limit nausea and GI effects; a black box warning for thyroid C-cell tumors derives from rodent data only.
- Baseline labs, eye exam, and monitoring of A1C, weight, body composition, and heart rate support individualized follow-up.
Questions? Our Provider Care Team is here to help.
We'd love to help you determine the best next steps on your Cellular Medicine journey.
Continue your learning journey
VIEW ALLAging-Associated Decline of Phosphatidylcholine Synthesis is a Malleable Trigger of Natural Mitochondrial Aging
Dr. Seeds explores how age-related decline in phosphatidylcholine synthesis may contribute to mitochondrial aging and why that matters in Cellular Medicine. This discussion connects membrane integrity, mitochondrial function, methylation, and metabolic resilience, while highlighting how this pathway may be more modifiable than we once thought.
1. Managing shingles outbreaks in GLP-1 patient through peptides (0:40)
2. Peptide strategies in suspected ALS (15:56)
3. Improving durability in dementia treatment (25:08)
In this bonus episode from the MM15 Virtual Summit, Dr. Seeds addresses an important question around the use of GLP-1s for metabolic balancing in patients who do not need to lose weight. He shares his perspective on what may be considered microdosing, along with the clinical thought process he uses when determining appropriate dosing in these more nuanced cases.
Additional questions from the MM15 Virtual Summit can be found in our accompanying article here: [insert article link]
Access the full MM15 Course here: Mastermind 15 on Aesthetics
The Limits of Alternative Peptide Delivery
Dr. Seeds reviews oral, sublingual, and transdermal peptide delivery, and explains why subcutaneous injection remains the gold standard for most peptides. (Question Link)
A Deeper Look at the RAAS System
Dr. Seeds uses this Rabbit Holes episode to build on Journal Club Episode 87, revisiting the renin-angiotensin-aldosterone system and its broader role in cellular signaling. The discussion focuses on receptor balance, local tissue effects, and the mechanisms linking RAS disruption to inflammation, fibrosis, and mitochondrial stress.(Article Link)
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation
Dr. Seeds unpacks how RAS receptor balance drives inflammation, fibrosis, mitochondrial dysfunction, and tissue remodeling, far beyond its classical role in blood pressure regulation. (Article Link)
1. SSRI tapering resistance, anxiety during weaning (0:40)
2. Progressive multifocal dystonia (13:27)
3. Complex type 2 diabetes case in a lean, athletic patient (28:32)